Q1 Earnings Estimate for CRBP Issued By Wedbush

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Equities researchers at Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued on Monday, October 20th. Wedbush analyst R. Driscoll expects that the biopharmaceutical company will post earnings of ($1.15) per share for the quarter. Wedbush has a “Outperform” rating and a $38.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. Wedbush also issued estimates for Corbus Pharmaceuticals’ Q2 2026 earnings at ($1.32) EPS, Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.15) EPS and FY2026 earnings at ($4.68) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.55) by $0.11.

Several other research firms also recently weighed in on CRBP. Piper Sandler restated an “overweight” rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Corbus Pharmaceuticals in a report on Monday. Benchmark reaffirmed a “reduce” rating on shares of Corbus Pharmaceuticals in a report on Monday. Finally, Oppenheimer reduced their price objective on Corbus Pharmaceuticals from $56.00 to $53.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $45.86.

Corbus Pharmaceuticals Price Performance

CRBP opened at $17.74 on Wednesday. Corbus Pharmaceuticals has a one year low of $4.64 and a one year high of $20.77. The business has a 50 day simple moving average of $12.18 and a two-hundred day simple moving average of $9.29. The firm has a market capitalization of $217.49 million, a price-to-earnings ratio of -3.73 and a beta of 2.84.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Corton Capital Inc. acquired a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at approximately $86,000. Marshall Wace LLP acquired a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at approximately $137,000. Baker Avenue Asset Management LP bought a new position in shares of Corbus Pharmaceuticals in the second quarter valued at approximately $138,000. Y Intercept Hong Kong Ltd bought a new stake in Corbus Pharmaceuticals during the second quarter worth approximately $141,000. Finally, Stonepine Capital Management LLC acquired a new position in Corbus Pharmaceuticals in the 1st quarter worth approximately $186,000. 64.64% of the stock is owned by hedge funds and other institutional investors.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.